Advertisement
The Notice of the AGM and EGM is available for the public at the USSecurities Exchange Edgar site: http://www.sec.gov/ and at the IsraelSecurities Authority's site: www.magna.isa.gov.il .
Advertisement
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development oftherapeutics for the treatment of diabetic neuropathic pain and HCV. XTL isdeveloping Bicifadine, a serotonin and norepinephrine reuptake inhibitor, forthe treatment of diabetic neuropathic pain, which is currently in a Phase 2bstudy. XTL has out-licensed its novel pre-clinical HCV small moleculeinhibitor program. XTL also has an active in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. XTL is publiclytraded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).At the AGM it is proposed that: -- the annual report and financial statements for the year ended December 31, 2007 be received; -- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the Company's auditors and the fixing of their remuneration be authorized; and -- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy, and Laurence Charney be re-appointed as Directors of the Company. At the EGM it is proposed that: -- the grant of options to Michael Weiss and Ben-Zion Weiner as detailed in the Notice be approved; -- the grant of options to Ben-Zion Weiner and William Kennedy as detailed in the Notice be approved; and -- the remuneration terms for Laurence Charney as detailed in the Notice be approved.
SOURCE XTL Biopharmaceuticals Ltd.
